After a soft Q2 due to COVID-19, Darzalex hit the blockbuster mark in Q3 driven by the robust uptake of the subcutaneous formulation and the resulting market share gain in the frontline multiple myeloma setting. Given its convenient administration, the drug should be a key growth driver going forward. Moreover, the recently-approved Kesimpta could help Genmab make a mark in the multiple sclerosis space. More details on the R&D pipeline at the Capital Markets Day next week.
05 Nov 2020
Strong Q3 led by the subcutaneous formulation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q3 led by the subcutaneous formulation
After a soft Q2 due to COVID-19, Darzalex hit the blockbuster mark in Q3 driven by the robust uptake of the subcutaneous formulation and the resulting market share gain in the frontline multiple myeloma setting. Given its convenient administration, the drug should be a key growth driver going forward. Moreover, the recently-approved Kesimpta could help Genmab make a mark in the multiple sclerosis space. More details on the R&D pipeline at the Capital Markets Day next week.